Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 1, 2025

Study Completion Date

June 30, 2025

Conditions
Hepatocellular Carcinoma
Trial Locations (1)

050000

RECRUITING

HebeiMUTH, Shijiazhuang

All Listed Sponsors
lead

Hebei Medical University Third Hospital

OTHER